Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


EMA Set For More Staff Losses & Activity Cuts Next Year

Executive Summary

The latest EMA management board meeting heard an update on the situation regarding Brexit-related staff losses and recruitment, and was told that an additional set of temporary suspensions or reductions in its activities might be necessary from the beginning of 2019.

You may also be interested in...

EMA Updates On Brexit Progress With ‘At-Risk’ Drugs And Staffing Issues

The European Medicines Agency has given an update on its Brexit preparations, including progress with dealing with “at-risk” medicines, staff retention and recruitment issues, and the resumption of some activities that have been temporarily shelved or cut back.

UK Court Ruling Could Impair EMA’s Ability To Do Its Job

A UK judge has said the European Medicines Agency cannot escape the lease on its London premises after Brexit, meaning the agency may have to pay double rent when it moves to Amsterdam. The EMA believes this will affect its ability to carry out its responsibilities as an EU agency.

EU Drug Filings To Fall Slightly In 2019, But Scientific Advice On The Up

The EMA expects initial applications for drug approvals to decline slightly next year, with the budget also down a little because of Brexit uncertainty. The agency's management board reported on its visit to the agency’s future home in Amsterdam. 

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts